Author: Donald Light
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
The Risks of Prescription Drugs
Author: Donald Light
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
Ten Drugs
Author: Thomas Hager
Publisher: Abrams
ISBN: 1683355318
Category : Medical
Languages : en
Pages : 342
Book Description
“The stories are skillfully told and entirely entertaining . . . An expert, mostly feel-good book about modern medicine” from the award-winning author (Kirkus Reviews, starred review). Behind every landmark drug is a story. It could be an oddball researcher’s genius insight, a catalyzing moment in geopolitical history, a new breakthrough technology, or an unexpected but welcome side effect discovered during clinical trials. Piece together these stories, as Thomas Hager does in this remarkable, century-spanning history, and you can trace the evolution of our culture and the practice of medicine. Beginning with opium, the “joy plant,” which has been used for 10,000 years, Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book. “[An] absorbing new book.” —The New York Times Book Review “[A] well-written and engaging chronicle.” —The Wall Street Journal “Lucidly informative and compulsively readable.” —Publishers Weekly “Entertaining [and] insightful.” —Booklist “Well-written, well-researched and fascinating to read Ten Drugs provides an insightful look at how drugs have shaped modern medical practices. Towards the end of the book Hager writes that he ‘came away surprised by some of the things he had learned.’ I had the very same reaction.” —Penny Le Couteur, coauthor of Napoleon’s Buttons: How 17 Molecules Changed History
Publisher: Abrams
ISBN: 1683355318
Category : Medical
Languages : en
Pages : 342
Book Description
“The stories are skillfully told and entirely entertaining . . . An expert, mostly feel-good book about modern medicine” from the award-winning author (Kirkus Reviews, starred review). Behind every landmark drug is a story. It could be an oddball researcher’s genius insight, a catalyzing moment in geopolitical history, a new breakthrough technology, or an unexpected but welcome side effect discovered during clinical trials. Piece together these stories, as Thomas Hager does in this remarkable, century-spanning history, and you can trace the evolution of our culture and the practice of medicine. Beginning with opium, the “joy plant,” which has been used for 10,000 years, Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book. “[An] absorbing new book.” —The New York Times Book Review “[A] well-written and engaging chronicle.” —The Wall Street Journal “Lucidly informative and compulsively readable.” —Publishers Weekly “Entertaining [and] insightful.” —Booklist “Well-written, well-researched and fascinating to read Ten Drugs provides an insightful look at how drugs have shaped modern medical practices. Towards the end of the book Hager writes that he ‘came away surprised by some of the things he had learned.’ I had the very same reaction.” —Penny Le Couteur, coauthor of Napoleon’s Buttons: How 17 Molecules Changed History
Managed Care Pharmacy Practice
Author: Navarro
Publisher: Jones & Bartlett Publishers
ISBN: 076378883X
Category : Medical
Languages : en
Pages : 659
Book Description
Managed Care Pharmacy Practice, Second Edition offers information critical to the development and operation of a managed care pharmacy program. The text also covers the changes that have taken place within the delivery of pharmacy services, as well as the evolving role of pharmacists.
Publisher: Jones & Bartlett Publishers
ISBN: 076378883X
Category : Medical
Languages : en
Pages : 659
Book Description
Managed Care Pharmacy Practice, Second Edition offers information critical to the development and operation of a managed care pharmacy program. The text also covers the changes that have taken place within the delivery of pharmacy services, as well as the evolving role of pharmacists.
The Drug Book
Author: Michael C. Gerald
Publisher: Union Square + ORM
ISBN: 1402792328
Category : Medical
Languages : en
Pages : 882
Book Description
“A beautiful and well-researched historical guide to significant drugs” from the author of The Complete Idiot’s Guide to Prescription Drugs (Library Journal). Throughout history, humans everywhere have searched for remedies to heal our bodies and minds. Covering everything from ancient herbs to cutting-edge chemicals, this book in the hugely popular Milestones series looks at 250 of the most important moments in the development of life-altering, life-saving, and sometimes life-endangering pharmaceuticals. Illustrated entries feature ancient drugs like alcohol, opium, and hemlock; the smallpox and the polio vaccines; homeopathic cures; and controversial medical treatments like ether, amphetamines, and Xanax—while shining a light on the scientists, doctors, and companies who brought them to us. “These true tales of discovery in The Drug Book by Michael C. Gerald might change the way you think about your medicine.” —The Healthy “An excellent starting point for student researchers and is very browsable for the general reader.” —Booklist
Publisher: Union Square + ORM
ISBN: 1402792328
Category : Medical
Languages : en
Pages : 882
Book Description
“A beautiful and well-researched historical guide to significant drugs” from the author of The Complete Idiot’s Guide to Prescription Drugs (Library Journal). Throughout history, humans everywhere have searched for remedies to heal our bodies and minds. Covering everything from ancient herbs to cutting-edge chemicals, this book in the hugely popular Milestones series looks at 250 of the most important moments in the development of life-altering, life-saving, and sometimes life-endangering pharmaceuticals. Illustrated entries feature ancient drugs like alcohol, opium, and hemlock; the smallpox and the polio vaccines; homeopathic cures; and controversial medical treatments like ether, amphetamines, and Xanax—while shining a light on the scientists, doctors, and companies who brought them to us. “These true tales of discovery in The Drug Book by Michael C. Gerald might change the way you think about your medicine.” —The Healthy “An excellent starting point for student researchers and is very browsable for the general reader.” —Booklist
Drugs and Drug Policy
Author: Mark A.R. Kleiman
Publisher: Oxford University Press
ISBN: 0199831386
Category : Political Science
Languages : en
Pages : 258
Book Description
While there have always been norms and customs around the use of drugs, explicit public policies--regulations, taxes, and prohibitions--designed to control drug abuse are a more recent phenomenon. Those policies sometimes have terrible side-effects: most prominently the development of criminal enterprises dealing in forbidden (or untaxed) drugs and the use of the profits of drug-dealing to finance insurgency and terrorism. Neither a drug-free world nor a world of free drugs seems to be on offer, leaving citizens and officials to face the age-old problem: What are we going to do about drugs? In Drugs and Drug Policy, three noted authorities survey the subject with exceptional clarity, in this addition to the acclaimed series, What Everyone Needs to Know®. They begin, by defining "drugs," examining how they work in the brain, discussing the nature of addiction, and exploring the damage they do to users. The book moves on to policy, answering questions about legalization, the role of criminal prohibitions, and the relative legal tolerance for alcohol and tobacco. The authors then dissect the illicit trade, from street dealers to the flow of money to the effect of catching kingpins, and show the precise nature of the relationship between drugs and crime. They examine treatment, both its effectiveness and the role of public policy, and discuss the beneficial effects of some abusable substances. Finally they move outward to look at the role of drugs in our foreign policy, their relationship to terrorism, and the ugly politics that surround the issue. Crisp, clear, and comprehensive, this is a handy and up-to-date overview of one of the most pressing topics in today's world. What Everyone Needs to Know® is a registered trademark of Oxford University Press.
Publisher: Oxford University Press
ISBN: 0199831386
Category : Political Science
Languages : en
Pages : 258
Book Description
While there have always been norms and customs around the use of drugs, explicit public policies--regulations, taxes, and prohibitions--designed to control drug abuse are a more recent phenomenon. Those policies sometimes have terrible side-effects: most prominently the development of criminal enterprises dealing in forbidden (or untaxed) drugs and the use of the profits of drug-dealing to finance insurgency and terrorism. Neither a drug-free world nor a world of free drugs seems to be on offer, leaving citizens and officials to face the age-old problem: What are we going to do about drugs? In Drugs and Drug Policy, three noted authorities survey the subject with exceptional clarity, in this addition to the acclaimed series, What Everyone Needs to Know®. They begin, by defining "drugs," examining how they work in the brain, discussing the nature of addiction, and exploring the damage they do to users. The book moves on to policy, answering questions about legalization, the role of criminal prohibitions, and the relative legal tolerance for alcohol and tobacco. The authors then dissect the illicit trade, from street dealers to the flow of money to the effect of catching kingpins, and show the precise nature of the relationship between drugs and crime. They examine treatment, both its effectiveness and the role of public policy, and discuss the beneficial effects of some abusable substances. Finally they move outward to look at the role of drugs in our foreign policy, their relationship to terrorism, and the ugly politics that surround the issue. Crisp, clear, and comprehensive, this is a handy and up-to-date overview of one of the most pressing topics in today's world. What Everyone Needs to Know® is a registered trademark of Oxford University Press.
Drugs for Life
Author: Joseph Dumit
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Finding What Works in Health Care
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309164257
Category : Medical
Languages : en
Pages : 267
Book Description
Healthcare decision makers in search of reliable information that compares health interventions increasingly turn to systematic reviews for the best summary of the evidence. Systematic reviews identify, select, assess, and synthesize the findings of similar but separate studies, and can help clarify what is known and not known about the potential benefits and harms of drugs, devices, and other healthcare services. Systematic reviews can be helpful for clinicians who want to integrate research findings into their daily practices, for patients to make well-informed choices about their own care, for professional medical societies and other organizations that develop clinical practice guidelines. Too often systematic reviews are of uncertain or poor quality. There are no universally accepted standards for developing systematic reviews leading to variability in how conflicts of interest and biases are handled, how evidence is appraised, and the overall scientific rigor of the process. In Finding What Works in Health Care the Institute of Medicine (IOM) recommends 21 standards for developing high-quality systematic reviews of comparative effectiveness research. The standards address the entire systematic review process from the initial steps of formulating the topic and building the review team to producing a detailed final report that synthesizes what the evidence shows and where knowledge gaps remain. Finding What Works in Health Care also proposes a framework for improving the quality of the science underpinning systematic reviews. This book will serve as a vital resource for both sponsors and producers of systematic reviews of comparative effectiveness research.
Publisher: National Academies Press
ISBN: 0309164257
Category : Medical
Languages : en
Pages : 267
Book Description
Healthcare decision makers in search of reliable information that compares health interventions increasingly turn to systematic reviews for the best summary of the evidence. Systematic reviews identify, select, assess, and synthesize the findings of similar but separate studies, and can help clarify what is known and not known about the potential benefits and harms of drugs, devices, and other healthcare services. Systematic reviews can be helpful for clinicians who want to integrate research findings into their daily practices, for patients to make well-informed choices about their own care, for professional medical societies and other organizations that develop clinical practice guidelines. Too often systematic reviews are of uncertain or poor quality. There are no universally accepted standards for developing systematic reviews leading to variability in how conflicts of interest and biases are handled, how evidence is appraised, and the overall scientific rigor of the process. In Finding What Works in Health Care the Institute of Medicine (IOM) recommends 21 standards for developing high-quality systematic reviews of comparative effectiveness research. The standards address the entire systematic review process from the initial steps of formulating the topic and building the review team to producing a detailed final report that synthesizes what the evidence shows and where knowledge gaps remain. Finding What Works in Health Care also proposes a framework for improving the quality of the science underpinning systematic reviews. This book will serve as a vital resource for both sponsors and producers of systematic reviews of comparative effectiveness research.
Undoing Drugs
Author: Maia Szalavitz
Publisher: Hachette GO
ISBN: 9780738285764
Category :
Languages : en
Pages : 304
Book Description
Journalist and author of the New York Times bestselling Unbroken Brain tackles the revolutionary concept of harm reduction, how it can transform the treatment of addiction, and how it holds the potential to revolutionize our treatment of behavioral and societal issues. In her New York Times bestseller Unbroken Brain, journalist Maia Szalavitz took an unflinching look at addiction, challenging the idea of the "broken brain" to offer a groundbreaking perspective on addiction as a learning disorder. Now she turns her keen eye and narrative powers to the surprisingly simple--and extremely divisive--practice of harm reduction, which is a revolutionary means to solving the drug addiction crisis. Drug overdoses now kill more Americans annually than guns, cars or breast cancer. But in the name of "sending the right message," we have criminalized drug addiction, denied those who are addicted medical care, housing and other benefits, and have deliberately allowed the spread of fatal diseases. Yet there is an alternative to our present system, one that has been proven to work, but which runs counter to the received wisdom of our criminal and medical industrial complexes. It is called harm reduction. A surprisingly simple idea with enormous power, harm reduction takes the focus off of drug use and instead works to minimize associated damage. It represents the philosophy behind needle exchange programs and providing heroin addicts with the overdose medication naloxone instead of arresting them. It is focused not on punishing pleasure but on minimizing harm; in essence, it is a wholesale refutation of the American way of justice. Undoing Drugs tells the story of harm reduction. It will show how this concept has begun to transform the treatment of addiction and how it holds the potential to revolutionize how we deal with a range of other urgent behavioral and societal issues. Harm reduction challenges people to prioritize radical empathy and kindness over punishment as a way of not only dealing with drug use, but also in questions related to racism, sexism, disability and inequality. And, as Szalavitz shows, it says unequivocally that we must be more concerned about saving lives and health than about criminalizing quality-of-life crimes. Szalavitz argues for a practical application of the Hippocratic oath to "First, do no harm" beyond medicine and to those who urgently need it most.
Publisher: Hachette GO
ISBN: 9780738285764
Category :
Languages : en
Pages : 304
Book Description
Journalist and author of the New York Times bestselling Unbroken Brain tackles the revolutionary concept of harm reduction, how it can transform the treatment of addiction, and how it holds the potential to revolutionize our treatment of behavioral and societal issues. In her New York Times bestseller Unbroken Brain, journalist Maia Szalavitz took an unflinching look at addiction, challenging the idea of the "broken brain" to offer a groundbreaking perspective on addiction as a learning disorder. Now she turns her keen eye and narrative powers to the surprisingly simple--and extremely divisive--practice of harm reduction, which is a revolutionary means to solving the drug addiction crisis. Drug overdoses now kill more Americans annually than guns, cars or breast cancer. But in the name of "sending the right message," we have criminalized drug addiction, denied those who are addicted medical care, housing and other benefits, and have deliberately allowed the spread of fatal diseases. Yet there is an alternative to our present system, one that has been proven to work, but which runs counter to the received wisdom of our criminal and medical industrial complexes. It is called harm reduction. A surprisingly simple idea with enormous power, harm reduction takes the focus off of drug use and instead works to minimize associated damage. It represents the philosophy behind needle exchange programs and providing heroin addicts with the overdose medication naloxone instead of arresting them. It is focused not on punishing pleasure but on minimizing harm; in essence, it is a wholesale refutation of the American way of justice. Undoing Drugs tells the story of harm reduction. It will show how this concept has begun to transform the treatment of addiction and how it holds the potential to revolutionize how we deal with a range of other urgent behavioral and societal issues. Harm reduction challenges people to prioritize radical empathy and kindness over punishment as a way of not only dealing with drug use, but also in questions related to racism, sexism, disability and inequality. And, as Szalavitz shows, it says unequivocally that we must be more concerned about saving lives and health than about criminalizing quality-of-life crimes. Szalavitz argues for a practical application of the Hippocratic oath to "First, do no harm" beyond medicine and to those who urgently need it most.
Bottle of Lies
Author: Katherine Eban
Publisher: HarperCollins
ISBN: 0063054108
Category : Medical
Languages : en
Pages : 523
Book Description
A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday With a new postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
Publisher: HarperCollins
ISBN: 0063054108
Category : Medical
Languages : en
Pages : 523
Book Description
A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday With a new postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
Facing Addiction in America
Author: Office of the Surgeon General
Publisher: Createspace Independent Publishing Platform
ISBN: 9781974580620
Category :
Languages : en
Pages : 420
Book Description
All across the United States, individuals, families, communities, and health care systems are struggling to cope with substance use, misuse, and substance use disorders. Substance misuse and substance use disorders have devastating effects, disrupt the future plans of too many young people, and all too often, end lives prematurely and tragically. Substance misuse is a major public health challenge and a priority for our nation to address. The effects of substance use are cumulative and costly for our society, placing burdens on workplaces, the health care system, families, states, and communities. The Report discusses opportunities to bring substance use disorder treatment and mainstream health care systems into alignment so that they can address a person's overall health, rather than a substance misuse or a physical health condition alone or in isolation. It also provides suggestions and recommendations for action that everyone-individuals, families, community leaders, law enforcement, health care professionals, policymakers, and researchers-can take to prevent substance misuse and reduce its consequences.
Publisher: Createspace Independent Publishing Platform
ISBN: 9781974580620
Category :
Languages : en
Pages : 420
Book Description
All across the United States, individuals, families, communities, and health care systems are struggling to cope with substance use, misuse, and substance use disorders. Substance misuse and substance use disorders have devastating effects, disrupt the future plans of too many young people, and all too often, end lives prematurely and tragically. Substance misuse is a major public health challenge and a priority for our nation to address. The effects of substance use are cumulative and costly for our society, placing burdens on workplaces, the health care system, families, states, and communities. The Report discusses opportunities to bring substance use disorder treatment and mainstream health care systems into alignment so that they can address a person's overall health, rather than a substance misuse or a physical health condition alone or in isolation. It also provides suggestions and recommendations for action that everyone-individuals, families, community leaders, law enforcement, health care professionals, policymakers, and researchers-can take to prevent substance misuse and reduce its consequences.